home / stock / axim / axim news

AXIM News and Press, Axim Biotechnologies Inc From 05/10/22

Stock Information
Company Name: Axim Biotechnologies Inc
Stock Symbol: AXIM
Market: OTC
Website: aximbiotech.com
Menu
AXIM AXIM Quote AXIM Short AXIM News AXIM Articles AXIM Message Board
Get AXIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AXIM - AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it h...
AXIM - AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Disease (DED), announced toda...

AXIM - AXIM Biotechnologies CEO Issues Letter to Shareholders

Summary: AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system Plans to address largely underserved DED diagnosis market with patent pending tear collection method and approved tests, supported by world-class DED management team S...

AXIM - AXIM Biotechnologies develops test for biomarker of dry eye disease

AXIM Biotechnologies (OTCQB:AXIM) said it successfully developed a rapid quantitative tear test for matrix metalloproteinase (MMP) MMP-9, an inflammatory biomarker for Dry Eye disease. "Currently available MMP-9 testing does not detect a reduction in tear MMP-9 levels until the conc...
AXIM - AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Disease

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc ( OTCQB: AXIM ) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that it has suc...

AXIM - AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test

SAN DIEGO, March 07, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced that is has shifted its f...

AXIM - AXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch

AXIM is driven to positively transform the state of Dry Eye Disease (DED) testing and diagnosis The company will deploy industry leader IUL’s state-of-the-art iPeak readers Company Adds Veteran Lab Testing Exec Barry Craig AXIM develops and files for a...
AXIM - CDC Publishes AXIM® Biotechnologies-Sponsored Study on COVID-19 Neutralizing Antibodies

SAN DIEGO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics, oncological research, and dry eye disease, ...

AXIM - AXIM Biotechnologies Applauds FDA's Recent COVID-19 Test Policies to Support Rapid Neutralizing Antibody Tests

SAN DIEGO, Nov. 18, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today applauds...

AXIM - AXIM Biotechnologies Partners with Arizona State University to Determine Antibody Levels Against COVID-19

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting COVID-19 diagnostics and oncological research, announced today th...
Previous 10 Next 10